|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | ||||||
| Short-term investments | ||||||
| Prepaid expenses and other current assets | ||||||
| Total current assets | ||||||
| Property and equipment, net | ||||||
| Other long-term assets | ||||||
| Total assets | ||||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | ||||||
| Accrued research and development expenses | ||||||
| Accrued and other current liabilities | ||||||
| Total current liabilities | ||||||
| Convertible preferred stock, $0.0001 par value; 0 and 180,059,639 shares authorized, as of December 31, 2021 and 2020, respectively; 0 and 21,435,632 issued and outstanding as of December 31, 2021 and 2020, respectively; aggregate liquidation preference of $0 as of December 31, 2021 | ||||||
| Stockholders' equity (deficit): | ||||||
| Preferred stock, $0.0001 par value; 10,000,000 and 0 shares authorized as of December 31, 2021 and 2020, respectively; 0 issued and outstanding as of December 31, 2021 and 2020, respectively | ||||||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2022; and December 31, 2021; 33,815,999 and 33,531,743 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively | ||||||
| Additional paid-in capital | ||||||
| Accumulated other comprehensive loss | ||||||
| Accumulated deficit | ||||||
| Total stockholders' equity | ||||||
| Total liabilities and stockholders' equity |
Loading...
